×
Indication
×
BLINCYTO® (blinatumomab) is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.
This site is intended for US health care professionals only.
Indication
BLINCYTO® (blinatumomab) for injection 35 mcg single-use vial
RECONSTITUTION AND PREPARATION OF BLINCYTO® (blinatumomab)
ADMIX VIDEOS

These videos do not take the place of the reconstitution and preparation instructions located in the full Prescribing Information (PI). Please refer to the PI for specific instructions to prepare BLINCYTO®.

Special Considerations for Admixing BLINCYTO®
  • IV Solution Stabilizer is provided with the BLINCYTO® package and is used to coat the prefilled IV bag prior to addition of reconstituted BLINCYTO® to prevent adhesion of BLINCYTO® to IV bags and IV lines. Therefore, add IV Solution Stabilizer to the IV bag containing 0.9% Sodium Chloride. Do not use IV Solution Stabilizer for reconstitution of BLINCYTO®1

  • The entire volume of the admixed BLINCYTO® will be more than the volume administered to the patient (240 mL) to account for the priming of the IV line and to ensure that the patient will receive the full dose of BLINCYTO®1

  • When preparing an IV bag, remove air from IV bag. This is particularly important for use with an ambulatory infusion pump1

  • Use the specific volumes described in the admixing instructions to minimize errors in calculation1

VIEW STEPS FOR RECONSTITUTION AND PREPARATION
Back to Top
Reference:
  1. BLINCYTO® (blinatumomab) Prescribing Information, Amgen.